Induction: since evidence for optimal GC induction dos- ing in relapsing AAV is lacking, it was decided, to facili- tate recruitment, to allow investigators to choose from one of two GC regimens to take into consideration variability in disease severity and local GC prescribing practices (Table ...
Further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents can be accessed at: https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm. The full...
Additional information Various sections of the manuscript reviewed by:J.H. Best, Department of Pharmacy, University of Washington, Seattle, Washington, USA;A. Engert, Department of Internal Medicine I, University Hospital of Cologne, Köln, Germany;M. Fanale, Department of Lymphoma/Myeloma, The ...
Rituximab (RTX) is a chimeric monoclonal B-cell-depleting anti-CD20 antibody and it was the first anti-CD20 drug licensed for the treatment of B-cell lymphomas, refractory rheumatoid arthritis (RA) and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis [36]. Two randomized placebo-con...
26 Primary prophylaxis with trimethoprim/sulfamethoxazole may therefore be considered when prescribing rituximab. Immunisation As immunisation responses are compromised after treatment with rituximab,28 it is recommended that any required immunisations are given before treatment.1 Current guidelines recommend ...
Rituximab (Rituxan®, MabThera®, and Genentech/Roche) is a chimeric murine/human monoclonal IgG1k antibody directed against the CD20 antigen located at the surface of normal and malignant B lymphocytes.
of case notes (51 patients) from a single institution, rituximab SC was safely administered without antipyretic/antihistamine pre-medication. Among 307 doses of rituximab SC (patients had previously received rituximab IV cycle 1 with prophylaxis as specified in the prescribing information), two ...